Prognosis and treatment outcomes in anti-GBM (Goodpasture) disease
Prognosis of Anti-GBM Antibody Disease Through an International Cohort
The study will see how different treatments and early blood or urine markers at diagnosis relate to outcomes for people with anti-GBM (Goodpasture) disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Region Skane Academic / other |
| Locations | 1 site (Lund) |
| Trial ID | NCT07018024 on ClinicalTrials.gov |
What this trial studies
This observational project collects clinical records and diagnostic blood or urine samples to clarify prognosis in the rare anti-GBM condition. It has two overlapping arms: Arm A includes patients diagnosed from January 1, 2010 onward with available information about initial treatment and comes from centers with a search strategy that captures >80% of their patients. Arm B includes patients from any time period who have stored blood and/or urine samples from diagnosis and known six‑month survival status. Data from a single patient can be included in both arms to link treatment, biomarkers, and short‑term outcomes.
Who should consider this trial
Good fit: Ideal candidates are people diagnosed with anti-GBM disease who either (A) were diagnosed on or after January 1, 2010 with available initial treatment records from participating centers able to include >80% of their patients, or (B) have a blood or urine sample from the time of diagnosis and known survival status at six months.
Not a fit: People without available initial treatment records or without diagnostic blood/urine samples and six‑month survival information are unlikely to be included and thus may not benefit from this study's findings.
Why it matters
Potential benefit: If successful, the study could help clinicians predict outcomes and tailor treatment decisions using early biomarkers and real‑world treatment experience.
How similar studies have performed: Previous observational registries have provided some prognostic information in anti‑GBM disease, but biomarker‑guided outcome prediction is still limited and relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Arm A: Inclusion Criteria: * Anti-GBM disease diagnosed 01-01-2010 - 31-12-2027 * Available information about initial treatment Arm B: Inclusion Criteria: * Anti-GBM disease diagnosis (no time limit) * Available blood and/or urine sample at the time of diagnosis * Available information about patient survival at six months
Where this trial is running
Lund
- Lund — Lund, Sweden (Recruiting)
Study contacts
- Study coordinator: Mårten Segelmark, MD, PhD, Professor
- Email: marten.segelmark@med.lu.se
- Phone: +46702871990
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.